UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a 62 million DKK capital raise from a group of existing and new investors through issuance of new shares. The proceeds enable accelerated development of UNION’s clinical pipeline with the two lead molecules orismilast and niclosamide. UNION is developing orismilast modified release (MR) tablet as a potential first-in-class or best-in-class treatment for